

Terumo Australia Modern Slavery Statement 2022



Disclosure Note

The submitting entity is Terumo Australia Pty Ltd. This statement has been made on behalf of Terumo Australia Pty Ltd. Terumo Australia does not own or control any other entities.

This statement covers financial year (FY) 2022 from 1 April 2022 to 30 March 2023.

This statement has been approved by the Board of Terumo Australia Pty Ltd in their capacity as principal governing body of Terumo Australia Pty Ltd on 21 September 2023.

ABN 34 158 693 595

All dollar figures presented in this Statement are in AUD unless otherwise indicated.

Contents

About Terumo Australia	3
Our Values	3
Statement from our Board and Managing Director.....	4
Highlights	4
Reporting Criteria 1 & 2:	5
Our Organisational Structure	5
Our Governance Framework	6
Our Supply Chain – Terumo Australia	8
Reporting Criteria 3: Modern slavery risks in operations and supply chain	10
Reporting Criteria 4: Actions taken to assess and address risk	12
Reporting Criteria 5: Effectiveness Assessment.....	14
Continuous improvement.....	14
Reporting Criteria 6: Process of consultation with entities owned or controlled	15

About Terumo Australia

Terumo is a global medical device company originating from Japan. We pursue reliable quality and technology to contribute to healthcare in more than 160 countries and regions around the globe. At Terumo, we reduce patients' difficulties both mentally and physically, while delivering solutions that help solve various issues in medical settings. We promise to walk alongside healthcare professionals to continue to make a great contribution to society, now and into the future. Terumo Australia Pty Limited is a wholly-owned subsidiary of Terumo Asia Holdings Pty Ltd, a subsidiary of the Japanese multinational Terumo Corporation. Terumo Australia has partnered with healthcare professionals in Australia since 1973. We strive to be a trusted partner to patients and medical professionals throughout Australia and New Zealand. Terumo is active in medical fields such as cardiovascular, peripheral vascular, cardiology, and the general hospital arena. Terumo Australia operates with an extensive warehousing and distribution network, customer relations; and quality and regulatory functions.

Our Values

Since its establishment in 1921, Terumo has continued to build trust from patients and healthcare professionals. Under the unchanging Group Mission of "Contributing to Society through Healthcare", we provide products and services that respond to the changing needs of medical settings. In addition to the Group Mission, the Core Values connect Terumo associates around the world, and the Terumo Group Code of Conduct acts as a guide that all employees follow to act with the highest ethical standards.

Terumo Group associates, suppliers and business partners are expected to abide by our Core Values of Respect, Integrity, Care, Quality and Creativity.

Earning trust from society is critical for Terumo to continue to fulfil its corporate mission "Contributing to Society through Healthcare". Terumo, together with its all associates, strives to protect its reputation, which is an invaluable asset, and further build trust from society. To achieve this, every Terumo associate must make the right decisions and do the right thing. Terumo Group Code of Conduct is a guide for Terumo associates to make the right decisions in their everyday actions.

Terumo makes every effort to ensure that all associates around the world, not only directors and officers, pursue fair business, abide by laws and regulations, and follow the highest ethical standard for serving patients and healthcare professionals who use Terumo products.

Statement from our Board and Managing Director

Terumo Australia is pleased to present our second Modern Slavery Statement.

As we reflect on the past year, our society faces new challenges and new opportunities. There is an ongoing expectation that we conduct business in an ethical manner, and this is a responsibility Terumo treats with utmost importance while navigating new challenges post-pandemic. We are proud of the integrity and adaptability shown by our employees, and grateful for the opportunity for the ongoing business partnerships based on trust and respect.

Underpinning our mission of “Contributing to Society through healthcare” is our unwavering commitment to sustainability in its broadest sense, including managing and mitigating modern slavery and broader human rights risks. In 2022, we built upon our modern slavery action plan and roadmap to ensure we continue to operate responsibly to protect the people, communities, and environments where we conduct our operations and across our extended networks.

I am pleased to present this Statement, which was approved by the Board of Terumo Australia Pty Ltd on 21 September 2023.

Signed by Jeff SOO, Managing Director

Highlights

2022: Modern Slavery Risk Management Initiatives

In 2022 we implemented priority Year 2 actions outlined in our three-year Modern Slavery Action Plan (see Terumo Australia Modern Slavery Statement 2021 for details) and began to embed modern slavery risk management into our corporate systems and processes. We continued to engage with key internal stakeholders and uploaded our action plan onto our corporate project management platform to assign tasks, monitor progress and provide regular updates to management, our Board and our corporate headquarters in Japan.

A Standard Operating Procedure (SOP) was developed to ensure we comply with ongoing reporting requirements of the Modern Slavery Act. Modern slavery was incorporated into Terumo Australia’s corporate risk register and Global Compliance Violations Reporting (Whistleblower) and Anti-retaliation Policy.

We engaged our highest potential risk ‘original equipment manufacturer’ (OEM) supplier, encouraging this supplier to address issues (corrective actions) identified by our supply chain assessments completed in 2021. A modern slavery risk management compliance clause was also incorporated into the supply contract.

Expanding and refining our modern slavery due diligence initiatives is an ongoing process and we are working closely with our corporate procurement and sustainability teams in Japan to implement a practical and fit-for-purpose due diligence framework.

Modern slavery compliance reporting was formally added to our supply chain manager’s position description. We educated our Board of Directors, provided our staff with access to an eLearning course on modern slavery and included information on modern slavery risks in our induction training for new employees.

Our Plans for 2023

In 2023 we will review, evaluate and improve our modern slavery risk management program and extend this program to incorporate assessment of broader human rights risks also. Our priority will be to establish performance standards and evaluation criteria for our suppliers and develop and review corrective action plans with identified high-risk suppliers.

Our Plans Beyond 2023

Beyond 2023, we will review and evaluate the outcomes of our first three-year modern slavery action plan (2021 – 2023), refresh our supplier risk profile baseline and develop a new risk management framework and action plan that considers the outcomes of the Commonwealth Modern Slavery Act legislative review process.

Reporting Criteria 1 & 2:

Our Organisational Structure

Terumo Corporation (Tokyo Stock Exchange: 4543) (“Terumo Group”) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo group employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Terumo Corporation is the ultimate parent company of each of the entities comprising Terumo Australia Pty Ltd (ABN: 34 158 693 595).

Cardiac and Vascular Company	TIS Division (Terumo Interventional Systems)	Expanding the potential of vascular treatment to raise patient comfort
	Neurovascular Division (MicroVention)	Revolutionizing neurovascular intervention with unique technologies
	Cardiovascular Division (Terumo Cardiovascular) / HeartSheet Division	Providing lifesaving technologies to cardiac surgery teams around the world
	Vascular Graft Division (Terumo Aortic)	Excellent technological synergy to bring patients optimal aortic treatment

Medical Care Solutions Company	Hospital Care Solutions Division	Solving issues hospitals face by providing solutions to help improve the quality and safety of healthcare
	Life Care Solutions Division	Standing together with patients to propose solutions to fit each patient's needs
	Pharmaceutical Solutions Division	Utilizing unique technologies to add value to pharmaceuticals and contribute to better drug delivery
Blood and Cell Technologies Company	Blood and Cell Technologies Division	Unlocking the potential of blood and cells for patients and their quality of life

Our Governance Framework

Terumo Group adopted the organisational design of a Company with Audit and Supervisory Committee, as described in the Companies Act of Japan, to achieve the following goals, further strengthen its corporate governance framework, and to enhance its medium- to long term corporate value.

Strengthen audit and supervisory functions: The members of the Audit and Supervisory Committee shall have voting rights in meetings of the Board of Directors.

Enhance transparency and objectivity in management: By increasing the proportion of independent directors on the Board, transparency and objectivity in decision making will be enhanced at the Board level by reflecting opinions of the independent directors, which represent the perspective of shareholders and other stakeholders.

Expedite decision-making process: By promoting the appropriate delegation of the Board's authority to directors, group executive officers and/or executive officers, Terumo will further expedite its decision-making process and business development through a shift toward a monitoring-based approach for the Board.

In addition to the Terumo group high-level governance framework stated above, Terumo Australia is governed by following governance framework:

1. Board of Directors

The Board of Directors is defined in the Articles of Association of Terumo Australia. The Board is the ultimate decision-making body and has all powers, except for those reserved to the general shareholders' meeting by law or the Articles of Association and internal procedures of the Terumo group. The role of the Board is to pursue the long-term success of Terumo Australia by providing entrepreneurial leadership and enabling risks to be assessed and managed. The Board decides on Terumo Australia's values and strategy, its risk appetite and key policies.

2. Serious Issues

Serious Issues, as defined in an internal policy, are reported to the Managing Director of Terumo Australia. Managing Director of Terumo Australia reports Serious Issues to the Chairperson of Internal Control Committee (“ICC”) of Terumo Corporation, with copy to Audit/Supervisory Committee member nominated by the Audit/Supervisory Committee, the heads of the Terumo’s Internal Control Departments.

3. Supplemental provisions of Compliance Violations Reporting and Anti-Retaliation Policy for Terumo Australia

From 1 July 2019, the whistleblower protections in the Corporations Act have been expanded to provide greater protections for whistleblowers. Directors and other senior managers have obligations under the Corporations Act if they receive a report from a whistleblower. For complying with this legislation, a supplemental provision has been established. The supplemental provision has been made for supplementing the Terumo Global Compliance Violations Reporting and Anti Retaliation Policy.

4. Quality management system (ISO 9001)

This quality system is designed and maintained to assure that all healthcare products and services Terumo Australia have provided comply with relevant standards, regulations, and customer requirements. This quality system aligns with the strategic direction of Terumo Australia. External and internal issues relevant to the quality system are recognised and understood, with appropriate documentation maintained. All processes needed for the quality management system are listed under an internal quality manual, and the effectiveness of the processes are monitored through internal audits, management review, incident reporting systems, performance evaluations, external assessments, and risk management. All regulators shall be appropriately notified of plans for substantial changes to the Quality System or product range as applicable.

5. Compliance Officer

The Compliance Officer shall monitor the laws, regulations, best practices and peer practices of the industry, and report on a regularly basis to the Board such changes as will be required to update the compliance program, the systems and procedures, and in general of Terumo Australia’s business practices.

Our policies – Terumo Group

We have several Group policies and guidelines which require our associates (employees and contractors), suppliers and other stakeholders to protect and respect human rights as part of our day-to-day businesses. Policies apply to all Terumo Group entities including Australia, contribute to our Group Mission and are available on the Terumo Group website (see www.terumo.com). Summary information on our policies was provided in our 2021 Statement.

Our Operations – Terumo Australia







Terumo Australia is a sales and marketing affiliate for Australia and New Zealand. Terumo Australia’s main operations include distributing medical devices in our territory.

The products for which Terumo Australia has distributed are manufactured in and imported from countries outside Australia, such as Japan, the Philippines, Vietnam, China, and the United States. Terumo Australia’s supply chain also comprises suppliers of indirect goods and services (information technology, professional services, sales and marketing agencies and facilities). Examples of the goods and services procured are described in the next section.

Number of staff	Facilities	Annual turnover	Number of suppliers
70 associates in Australia and New Zealand	Offices in Sydney, Brisbane and Melbourne and four warehouses (Sydney, Perth and Auckland)	≈AU\$ 94M	220

Our Supply Chain – Terumo Australia

To ensure safety and reliability in healthcare, we view each issue to find the optimal solution. As well as product quality, we pursue excellence in all we do, from product supply to customer care. Our approach to supply chain management supports our mission “Contributing Society through Healthcare” by providing valued products and services in the healthcare market and by responding to the needs of patients and healthcare professionals. Data at a glance:

 Total spend: \$56.0M	 Total suppliers: 220	 Total categories: 21
 % spend on stock items: 70%	 No. of supplier countries: 13	 % suppliers in Australia: 83%

Our suppliers – Terumo Australia

Terumo Australia’s annual procurement spend is \$56 million with 220 direct (Tier 1) suppliers across our goods and services categories. This is a decrease of \$27M on our previous Modern Slavery Statement.

Terumo Australia has agreements with other Terumo Group global entities for the supply of inventory stock items and goods for sale to our valued customers in Australia and New Zealand. Approximately 70% of our annual procurement spend is with eleven Terumo Group entities located across nine countries.

The other 30% of our spend is with non-Terumo Group suppliers which include:

- Original Equipment Manufacturers (OEMs)
- Other specialty manufacturers
- Equipment, consumable and material suppliers
- Service providers such as logistics, facilities management and professional services.

Further work will be undertaken to better understand our extended supply chain and inherent modern slavery risks in our indirect (Tier 2) suppliers.

What we buy

Senty percent (70%) of our spend is on inventory stock items and goods for sale. The main categories of goods and services we procure from our direct suppliers and percent of our spend with each supplier is included in Table 1. Non-stock items include a wide range of goods and services, for example ICT hardware and facilities management services that support our operations across Australia and New Zealand.

Table 1: Key goods and services procured

Procurement category	Percent spend
Inventory stock items and goods for sale	70%
Corporate finance, fees, services and expenses	10%
Warehouse, materials handling and logistics services	10%
ICT Software, networking and support services	2%
Other Goods and Services *	4%
Real estate / property management services	1%
Professional services and consulting	2%
Recruitment fees and services	1%

*Other goods and services include:

Advertising, media, marketing and promotions

Office supplies and services

Civic organizations, sponsorships and partnerships

Building / facility systems maintenance services

Events, venues, excursions and entertainment

Utilities

Travel expenses, parking and accommodation

P&E and machinery leasing and hire

Print / mail provider and document management

Supplier countries

Approximately one quarter (23%) of our annual procurement spend and over three-quarters (83%) of our suppliers either have a presence in or are based in Australia. Most of our international suppliers are in Japan, New Zealand, Singapore and the United States. We also procure goods and services from a small number of suppliers in China, India, Ireland, the European Union, the Netherlands, Philippines, Poland, South Korea, Vietnam and the United Kingdom.

Reporting Criteria 3: Modern slavery risks in operations and supply chain

Our focus in FY22 was to build on our due diligence efforts to continuously improve modern slavery risk management across our operations and supply chain.

OPERATIONAL RISKS

Our 2021 Modern Slavery Statement documents the outcomes of the gap analysis undertaken by our Modern Slavery Working Group to identify our modern slavery governance maturity across five key areas:

- Management systems
- Human resources and recruitment
- Procurement and supply chain
- Risk management
- Customers and stakeholders

The analysis identified gaps and opportunities for better managing our response to modern slavery and human rights risks more broadly. The results of the Gap Analysis informed our Modern Slavery Action Plan and Roadmap, developed collaboratively with key representatives from across our organisation. We acknowledge that the Modern Slavery Gap Analysis was the starting point of an ongoing effort to identify and manage modern slavery risk and deliver against our global mission of 'Contributing to Society through Healthcare.'

While the gap analysis was not repeated in 2022, we implemented a new internal tracking system to measure progress in implementing our three-year action plan. Action plan deliverables were incorporated into our corporate project management platform to assign tasks, monitor progress and provide regular updates to management on program implementation.

As our business model has remained largely unchanged since publishing our 2021 Modern Slavery Statement, the identified low risk of modern slavery occurring in our direct business operations also remains unchanged. Despite this, we acknowledge that the risks of modern slavery remain through our supply chain, and business partnerships including those with other Terumo entities and other third-party relationships.

Importantly, our Board and leadership teams in Australia and Japan remains committed to identifying, assessing and addressing modern slavery risks in our operations and across our extended supply chain.

SUPPLY CHAIN RISKS

In 2021 we focused our efforts on obtaining a deeper understanding of our Tier 1 risks and the operational processes in place to manage those risks. We engaged external experts, SD Strategies, to help us document, assess and prioritise our direct (Tier 1) non-Terumo Group suppliers against modern slavery risk indicators (see Terumo Modern Slavery Statement 2021 for details).

Modern slavery supply chain risk assessments were not repeated in 2022. The spend, supplier and category risk analysis undertaken in 2021 established a modern slavery supplier risk baseline that we use to assess potential threats, evaluate vulnerabilities, and enhance our risk management program. It enables us to proactively identify and mitigate modern slavery risks, identify emerging threats (and opportunities), and to engage with our identified highest risk suppliers. We will repeat the modern slavery supplier risk prioritisation future reporting periods to recalibrate our potential supplier risk and improve management actions.

As expressed in our 2021 statement, we acknowledge that potential modern slavery risk is associated with Terumo Group suppliers, particularly in the lower tiers, and suppliers located in countries known to have higher risk for modern slavery such as China, Thailand and Vietnam.

In FY22 Terumo Group conducted a self-assessment questionnaire on compliance with employment and labour-related laws and regulations at the manufacturing sites of Terumo Group. This survey, which is conducted annually, includes questions about the implementation of education and awareness activities on harassment, the minimum age of employees, the implementation of measures to prevent forced labour and to ensure proper employment of migrant workers. As a result, no observations of non-compliance or of forced labour were found in FY22. Particularly, it was confirmed that mechanisms and efforts to prevent forced labour exist in all targeted sites. These mechanisms and efforts include ensuring employment contracts comply with applicable laws and regulations, recording working hours and paying appropriate overtime pay, providing training, and establishing available reporting systems.

In FY22 Terumo Group undertook screening surveys of nearly 2,000 direct material manufacturing supplier sites globally, identifying 165 high risk suppliers located in the high risk countries in terms of potential human rights impacts, corruption and environmental concerns. Indicators from the *International Trade Union Confederations (ITUC) Global Rights Index*, *Transparency International Corruption Perception Index* and the *Environment and Governance Risk: Equator Principles* were used to conduct the assessment.

Terumo Group conducted fact-finding surveys of these 165 suppliers related to human rights, environmental protection, safety and hygiene, ethics, and management systems using a *Self-Assessment Questionnaire (SAQ)*. To date, 121 suppliers have responded to the SAQ.

Where Critical, Major, or Minor concerns are identified, Terumo Group requests and guides improvements for the identified risks or issues through further supplier engagement or audits. For example, a supplier was identified as having concerns regarding human rights due to not having a policy prohibiting forced labour, Terumo Group guided the supplier to incorporate a policy into the company's code of conduct while considering local laws and regulations on preventing human trafficking, aiming to reduce Modern Slavery risks in the supply chain.

To date, no Critical human rights violation such as child labour, forced labour or illegal labour practices have been observed. Supplier surveys and improvement guidance use a risk- and -spend-based prioritisation approach and will continue to be promoted and expanded, including to new business partners.

Reporting Criteria 4: Actions taken to assess and address risk

In 2022 we worked to more effectively embed modern slavery risk management into existing systems and processes and implemented the following key actions:

Stakeholder engagement

We continued to engage internal and external stakeholders to raise awareness of the issue and encourage action to assess and address modern slavery risks. We worked with members of our Modern Slavery Working Group, Terumo Australia's Board, key internal managers and associates and a major high risk OEM supplier identified in 2021.

Our team regularly exchanges information on our program with ESG and procurement specialists in our headquarters in Japan.

During 2022, we collated and analysed requests for information from customers on steps we are taking to manage modern slavery risk to ensure we provide consistent and accurate responses.

Risk framework

In 2022 we updated the modern slavery component of our risk register and shared the outcomes of the review with our corporate headquarters in Japan to ensure a more consistent approach to managing risk among suppliers to our manufacturing facilities located in Asia, the Americas and the Middle East.

Systems and Processes

Our risk and compliance team developed a standard operating procedure (SOP) for reporting under the Modern Slavery Act. The SOP outlines processes, responsibilities, approvals and timeframes to implement annual actions and prepare a compliant Modern Slavery Statement. The procedure enables a consistent approach to the preparation and approval of statements moving forward. We updated the position description of our Supply Chain Manager to include a responsibility to comply with the Australian legislative reporting requirements.

Monitoring progress

Recognising that a potential obstacle to effectively implementing our modern slavery action plan is ensuring its delivery across our business units, we uploaded our action plan onto a centralised project coordination platform. The platform enables managers and our Working Group to monitor progress, coordinate implementation of the action plan and efficiently utilise internal resources. The platform is used to provide regular progress (and effectiveness) reports to departmental managers at Business Review Meetings, corporate headquarters and our Board of Directors.

Supplier due diligence

In 2022, we engaged our highest-risk OEM supplier encouraging them to develop an internal policy and action plan to address issues identified in our local 2021 supplier risk assessment (local SAQ). We developed a Human Rights Compliance Declaration for our personnel

recruitment service suppliers mandating that they take 'reasonable steps' to eliminate modern slavery from their supply chains, have no convictions related to modern slavery offences, and understand our global human rights policies. This will be sent to all potentially high risk suppliers in the 2023 reporting period.

Contract clause

We reviewed the T&C's for our contract with a major potentially high risk OEM supplier and included a clause requiring them to manage modern slavery risk in their operations and supply chains. The templated clause can be included in other goods and services contracts with new OEM suppliers or when existing contracts are renewed.

Awareness and training

Awareness raising, training and professional development are key aspects of our three-year modern slavery action plan and road map. In 2022, we delivered online modern slavery awareness training to our Board of Directors and provided access to a modern slavery eLearning course to our associates. We updated our induction and onboarding processes for new employees to include information on modern slavery risks.

Grievance and whistleblower processes

We updated the Supplementary Provisions of the Terumo Group's global Compliance Violations Reporting and Anti-Retaliation Policy which applies to Terumo Australia. The update added a new 'reportable issue' to the policy: "Any misconduct or suspected situations of modern slavery in Terumo Australia or other Terumo Group Company's operations or supply chains". Our associates were made aware of the change to the Policy which will also be included in staff induction training.

Reporting Criteria 5: Effectiveness

Assessment

The measures taken to date establish a continuous improvement process to develop internal capabilities and iteratively improve our systems and processes.

We continue to implement a business-wide review process to ensure we are making tangible progress towards achieving our modern slavery risk management goals and actions.

- Modern slavery issues are addressed collaboratively across relevant areas of the business and Terumo Group Japan on an ongoing basis.
- Monthly Review – Modern Slavery Working Group and report to the Senior Management Team
- Update Terumo Group (Japan) on progress, issues and achievements of the Terumo Australia Modern Slavery Program (annually)
- Modern Slavery Statement is reviewed, approved and signed off by the Board as per mandatory reporting requirements (annually).

Continuous improvement

Addressing modern slavery risk is complex and challenging. In FY22 we built on our 2021 initiatives, expanding our due diligence program, engaging internal and external stakeholders and integrating risk management principles into our systems and processes.

Our Modern Slavery Working Group led by our Risk and Compliance Officer and supported by our Board of Directors, strives for continuous improvement as we integrate modern slavery risk management into all aspects of our operations and purchasing decisions.

We expect our approach to evolve over time as we and the business community learn more about the risks and impacts of modern slavery globally.

Reporting Criteria 6: Process of consultation with entities owned or controlled

Terumo Australia does not own or control any other entities.

Terumo Australia is an entity owned and controlled by Terumo Group (Japan). We are working closely with Group procurement and sustainability teams to ensure a harmonised approach to managing modern slavery risk across the organisation and identify opportunities to share learnings from our program.

MODERN SLAVERY ACT 2018 (CTH) – STATEMENT ANNEXURE

Principal Governing Body Approval

This modern slavery statement was approved by the *principal governing body* of

the Board of Directors of Terumo Australia Pty Ltd

as defined by the *Modern Slavery Act 2018* (Cth)¹ (“the Act”) on 09/21/2023

Signature of Responsible Member

This modern slavery statement is signed by a *responsible member* of

the Board of Directors

as defined by the Act²:

DocuSigned by:

 867EE9B960684C1

Jeff Soo, Managing Director

Mandatory criteria

Please indicate the page number/s of your statement that addresses each of the mandatory criteria in section 16 of the Act:

Mandatory criteria	Page number/s
a) Identify the reporting entity.	2
b) Describe the reporting entity’s structure, operations and supply chains.	5
c) Describe the risks of modern slavery practices in the operations and supply chains of the reporting entity and any entities it owns or controls.	10
d) Describe the actions taken by the reporting entity and any entities it owns or controls to assess and address these risks, including due diligence and remediation processes.	12
e) Describe how the reporting entity assesses the effectiveness of these actions.	14
f) Describe the process of consultation on the development of the statement with any entities the reporting entity owns or controls (a joint statement must also describe consultation with the entity covered by the statement).*	15
g) Any other information that the reporting entity, or the entity giving the statement, considers relevant.**	N/A

* If your entity does not own or control any other entities and you are not submitting a joint statement, please include the statement ‘Do not own or control any other entities’ instead of a page number.

** You are not required to include information for this criterion if you consider your responses to the other six criteria are sufficient.

1. Section 4 of the Act defines a principal governing body as: (a) the body, or group of members of the entity, with primary responsibility for the governance of the entity; or (b) if the entity is of a kind prescribed by rules made for the purposes of this paragraph—a prescribed body within the entity, or a prescribed member or members of the entity.

2. Section 4 of the Act defines a responsible member as: (a) an individual member of the entity’s principal governing body who is authorised to sign modern slavery statements for the purposes of this Act; or (b) if the entity is a trust administered by a sole trustee—that trustee; or (c) if the entity is a corporation sole—the individual constituting the corporation; or (d) if the entity is under administration within the meaning of the *Corporations Act 2001*—the administrator; or (e) if the entity is of a kind prescribed by rules made for the purposes of this paragraph—a prescribed member of the entity.